Estatísticas

 array:19 [
  "pii" => "X2255553606030770"
  "issn" => "22555536"
  "doi" => "10.2223/JPED.1557"
  "estado" => "S300"
  "fechaPublicacion" => "2006-11-01"
  "documento" => "simple-article"
  "subdocumento" => "fla"
  "cita" => "J Pediatr (Rio J). 2006;82 Supl 2:166-72"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X2255553606030780"
    "issn" => "22555536"
    "doi" => "10.2223/JPED.1552"
    "estado" => "S300"
    "fechaPublicacion" => "2006-11-01"
    "documento" => "simple-article"
    "subdocumento" => "fla"
    "cita" => "J Pediatr (Rio J). 2006;82 Supl 2:173-80"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Novos anti-histamínicos: uma visão crítica"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "pt"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "173"
          "paginaFinal" => "180"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Inês Cristina Camelo-Nunes"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Inês"
              "apellidos" => "Cristina Camelo-Nunes"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2255553606030780?idApp=UINPBA000049"
    "url" => "/22555536/00000082000000S2/v1_202201170903/X2255553606030780/v0_202201170903/pt/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X2255553606030760"
    "issn" => "22555536"
    "doi" => "10.2223/JPED.1556"
    "estado" => "S300"
    "fechaPublicacion" => "2006-11-01"
    "documento" => "simple-article"
    "subdocumento" => "fla"
    "cita" => "J Pediatr (Rio J). 2006;82 Supl 2:153-65"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:9 [
      "idiomaDefecto" => true
      "titulo" => "Manejo farmacológico da hipertensão arterial pulmonar"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "pt"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "153"
          "paginaFinal" => "165"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Cláudia Pires Ricachinevsky, Sérgio Luís Amantéa"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Cláudia"
              "apellidos" => "Pires Ricachinevsky"
            ]
            1 => array:2 [
              "nombre" => "Sérgio"
              "apellidos" => "Luís Amantéa"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2255553606030760?idApp=UINPBA000049"
    "url" => "/22555536/00000082000000S2/v1_202201170903/X2255553606030760/v0_202201170903/pt/main.assets"
  ]
  "pt" => array:9 [
    "idiomaDefecto" => true
    "titulo" => "Inibidores de calcineurina no tratamento das dermatoses alérgicas"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "166"
        "paginaFinal" => "172"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Ana Paula Beltran Moschione Castro"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Ana"
            "apellidos" => "Paula Beltran Moschione Castro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup"><span class="elsevierStyleSup">a</span></span>"
                "identificador" => "12804"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:3 [
            "entidad" => "Mestre&#46; M&#233;dica assistente e respons&#225;vel&#44; Ambulat&#243;rio de Dermatite At&#243;pica&#44; Unidade de Alergia e Imunologia&#44; Instituto da Crian&#231;a&#44; Hospital de Cl&#237;nicas&#44; Faculdade de Medicina&#44; Universidade de S&#227;o Paulo &#40;USP&#41;&#44; S&#227;o Paulo&#44; SP&#46;"
            "etiqueta" => "a"
            "identificador" => "12804"
          ]
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => """
          <html><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To review the role of calcineurin inhibitors in the treatment of allergic dermatitis, focusing on mechanisms of action, efficacy and topical and systemic adverse effects.</p>\n
          \t\t\t\t\t\t   </span><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Sources</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Articles written in English and published in MEDLINE using the following keywords: pimecrolimus, tacrolimus, calcineurin inhibitors. Original articles that presented controlled and open studies for assessing efficacy, tolerability and adverse effects were selected. Review articles and case series were also evaluated; the latter was only considered for assessing adverse effects. The official websites of the Food and Drug Administration and of manufacturers of calcineurin inhibitors were also used.</p>\n
          \t\t\t\t\t\t   </span><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Summary of the findings</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">: The data showed that calcineurin inhibitors are efficient in the treatment of mild to severe atopic dermatitis, leading to improvement in symptoms, reduction in number of attacks and need of topical corticotherapy. Calcineurin inhibitors have good tolerability and few topical adverse effects. To date, there has been no evidence to support higher prevalence of neoplasia in patients using these drugs; however, an adequate pharmacovigilance system has been set up to assess this aspect.</p>\n
          \t\t\t\t\t\t   </span><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conclusions</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Calcineurin inhibitors, which are a new drug class in the treatment of allergic dermatitis, are efficient, well tolerated and have few adverse effects. Calcineurin inhibitors should always be used according to recommended guidelines, and patients should always be followed by the physician during and after their administration.</p>\n
          \t\t\t\t\t\t   </span></html>
          """
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Objective"
          ]
          1 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Sources"
          ]
          2 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Summary of the findings"
          ]
          3 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "pt" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<html><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objetivo</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Revisar o papel dos inibidores da calcineurina no tratamento das dermatoses al&eacute;rgicas, com &ecirc;nfase nos mecanismos de a&ccedil;&atilde;o, efic&aacute;cia e efeitos adversos t&oacute;picos e sist&ecirc;micos. </p></span><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Fontes dos dados</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Artigos de l&iacute;ngua inglesa publicados na MEDLINE, considerando as palavras chave: <i>pimecrolimus, tacrolimo, calcineurin inhibitors</i>. Foram selecionados os artigos originais que apresentaram estudos controlados e estudos abertos para avalia&ccedil;&atilde;o da efic&aacute;cia, tolerabilidade e eventos adversos. Tamb&eacute;m foram avaliados artigos de revis&atilde;o e relatos e s&eacute;rie de casos, sendo estes &uacute;ltimos considerados apenas para avalia&ccedil;&atilde;o de efeitos adversos. Foram consultados os <i>sites</i> oficiais da <i>Food and Drug Administration</i> e dos fabricantes de inibidores da calcineurina. </p></span><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">S&iacute;ntese dos dados</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Os dados mostraram que inibidores de calcineurina s&atilde;o eficientes no tratamento da dermatite at&oacute;pica leve a grave, levando a melhora dos sintomas, diminui&ccedil;&atilde;o do n&uacute;mero de crises e necessidade de corticoterapia t&oacute;pica. Apresentam boa tolerabilidade e poucos efeitos adversos t&oacute;picos. At&eacute; o momento, n&atilde;o h&aacute; evid&ecirc;ncias que sustentem a maior preval&ecirc;ncia de neoplasias nos pacientes que utilizam esses medicamentos; entretanto, um adequado sistema de farmacovigil&acirc;ncia est&aacute; montado para avaliar esse aspecto. </p></span><span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Conclus&otilde;es</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Os inibidores de calcineurina s&atilde;o uma nova classe de medicamentos para o tratamento das dermatoses al&eacute;rgicas. S&atilde;o eficazes, tolerados e com poucos efeitos adversos. Devem ser sempre utilizados de acordo com as orienta&ccedil;&otilde;es preconizadas, e os pacientes devem ser sempre acompanhados pelo m&eacute;dico durante e ap&oacute;s sua administra&ccedil;&atilde;o.</p></span></html>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Objetivo"
          ]
          1 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Fontes dos dados"
          ]
          2 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "S&iacute;ntese dos dados"
          ]
          3 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Conclus&otilde;es"
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "pt"
  "url" => "/22555536/00000082000000S2/v1_202201170903/X2255553606030770/v0_202201170903/pt/main.assets"
  "Apartado" => array:4 [
    "identificador" => "24842"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Artigo de revis&#227;o"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/22555536/00000082000000S2/v1_202201170903/X2255553606030770/v0_202201170903/pt/main.pdf?idApp=UINPBA000049&text.app=https://jped.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2255553606030770?idApp=UINPBA000049"
]